Germany Veterinary Analgesics Anti Inflammatory Market Size, Share, Growth, and Industry Analysis, By Drug Class (NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)CarprofenMeloxicamFirocoxibDeracoxibRobenacoxibKetoprofenFlunixin MeglumineTolfenamic Acid, OpioidsBuprenorphineButorphanolFentanyl (patches), Adjunctive AnalgesicsGabapentinAmantadineTramadol), By Animal Type (Companion AnimalsDogsCatsOthers (rabbits, ferrets, etc.), Livestock AnimalsCattleSwinePoultrySheep and GoatsHorses) and Forecast, 2026-2034

Germany Veterinary Analgesics Anti Inflammatory Market Trends

Shift Toward Multimodal and Longer-Acting Pain Management

Veterinary pain management is moving beyond single-agent therapy toward combinations of NSAIDs, adjunctive medication, weight control, rehabilitation, and newer biologic approaches. Boehringer Ingelheim identifies NSAIDs, nutrition, physical therapy, weight management, nutraceuticals, and adjunct therapy as components of multimodal osteoarthritis management. Meanwhile, Germany's livestock treatment base remains substantial: May 2026 data show around 21.0 million pigs and 10.4 million cattle.

Technology is also shifting toward longer-duration biologics. Zoetis launched Lenivia in the European Union in 2026 as a three-month anti-NGF monoclonal-antibody treatment for canine osteoarthritis pain, compared with monthly administration for Librela. Separately, German poultry slaughterhouses processed about 697.3 million birds and 1.569 billion kg of poultry in 2025, illustrating the scale of animal-health management across production systems.

Germany Veterinary Analgesics Anti-Inflammatory Market Drivers

Large Companion and Production Animal Treatment Base Supports Analgesic Utilization

Demand is supported by chronic musculoskeletal disorders in pets, surgical procedures, livestock disease management, and increasing attention to animal welfare. Germany maintained roughly 10.5 million cattle in November 2025, including 3.6 million dairy cows, while pig inventory reached 21.5 million animals across 15,190 holdings. By May 2026, pig inventory remained approximately 21.0 million despite the number of pig farms declining 3.6% year over year to 14,700. These concentrated animal populations increase the importance of efficient veterinary treatment protocols and professionally supervised anti-inflammatory therapy.

Germany Veterinary Analgesics Anti-Inflammatory Market Opportunities

Long-Acting Biologics and Multimodal Therapy Expand Pain-Control Options

Innovation in canine osteoarthritis creates opportunities for differentiated treatment pathways alongside conventional NSAIDs. Lenivia provides three-month pain control from one injection, while Librela uses monthly administration. A 56-day comparative study reported 44 dogs completing treatment with Librela versus 33 receiving meloxicam, with at least one adverse event reported in 4 and 17 dogs, respectively. Such technology broadens veterinarian choice while complementing established oral and injectable anti-inflammatory products.

Challenges in Germany Veterinary Analgesics Anti-Inflammatory Market

Balancing Efficacy, Compliance, Cost and Pharmacovigilance

Veterinary practices must balance convenient administration against clinical suitability and ongoing safety surveillance. By December 2024, nearly 25 million Librela doses had been distributed globally, while reported individual adverse-event signs remained below the EMA-defined rare threshold cited by Zoetis of 10 occurrences per 10,000 treated animals. At the same time, Germany's pig sector has consolidated sharply: May 2026 holdings were 40.0% below 2016 levels even though average animals per farm increased from roughly 1,100 to 1,400.

Germany Veterinary Analgesics Anti-Inflammatory Market Segmentation

The market is segmented by drug class, animal type, administration route, indication, distribution channel, and end user. Based strictly on supplied quantitative tables, NSAIDs hold approximately 48.4% of 2026 drug-class revenue, while companion animals represent approximately 56.9% of the separately reported animal-type total.

By Drug Class

NSAIDs—including carprofen, meloxicam, firocoxib, deracoxib, robenacoxib, ketoprofen, flunixin meglumine, and tolfenamic acid—form the largest drug class. Revenue increases from USD 86.14 million in 2025 to USD 92.06 million in 2026 and USD 156.64 million in 2034, representing a 6.87% CAGR and approximately 48.4% of the 2026 total.

Opioids, including buprenorphine, butorphanol and fentanyl patches, increase from USD 60.05 million in 2026 to USD 101.96 million by 2034 at 6.84% CAGR. Adjunctive analgesics—including gabapentin, amantadine and tramadol—advance from USD 37.92 million to USD 62.94 million at 6.54%.

By Animal Type

Companion animals—dogs, cats and other pets—constitute the largest segment at USD 107.95 million in 2026, approximately 56.9% of the supplied animal-type total. Revenue is forecast to reach USD 178.12 million by 2034 at a 6.46% CAGR.

Livestock animals—including cattle, swine, poultry, sheep, goats and horses—are the fastest-expanding animal category. Revenue increases from USD 81.92 million in 2026 to USD 141.17 million by 2034 at 7.04% CAGR, exceeding the companion-animal expansion rate by 0.58 percentage points.

By Route of Administration

The route structure comprises oral tablets, chewables, liquids/suspensions, injectable products, topical/transdermal patches and creams/gels, and other formulations. Quantified route-level revenue was not supplied; consequently, no unsupported market value or CAGR is assigned. The supplied total nevertheless advances from USD 190.03 million in 2026 to USD 321.54 million in 2034, a USD 131.51 million increase.

By Indication

Indications include post-operative pain, musculoskeletal disorders such as osteoarthritis, equine colic, fever and inflammation management, and infectious disease-associated pain. Quantitative indication-level splits were not supplied. Across the overall dataset, 2025-2034 revenue increases by USD 143.60 million, while the headline CAGR is 6.75%.

By Distribution Channel

Veterinary clinics and hospitals, retail pharmacies, online pharmacies, and feed stores/agricultural cooperatives constitute the distribution framework. Prescription intensity varies by drug and animal category. No channel-specific revenue data were provided; therefore, the USD 190.03 million 2026 total and USD 321.54 million 2034 forecast are not artificially allocated among channels.

By End User

Veterinarians, pet owners, livestock owners/farmers and animal-welfare organizations constitute the principal end-user groups. Veterinarians remain central to prescription, administration and safety monitoring. End-user revenue shares were not supplied, while the overall dataset indicates a 6.75% CAGR through 2034.

Germany Veterinary Analgesics Anti-Inflammatory Market Outlook

Germany is treated as one national market because no Bundesland or county revenue dataset was supplied. Accordingly, state-level market shares are not fabricated. National livestock activity nevertheless demonstrates geographic treatment intensity: Germany recorded approximately 10.5 million cattle and 21.5 million pigs in November 2025, while 2025 poultry slaughter reached about 697.3 million animals and 1.569 billion kg.

Top players in Germany Veterinary Analgesics Anti-Inflammatory Market

• Zoetis
• Boehringer Ingelheim
• Elanco Animal Health
• Merck Animal Health/MSD Animal Health
• Ceva Santé Animale
• Dechra Pharmaceuticals
• Vetoquinol
• Virbac
• Norbrook Laboratories
• Chanelle Pharma
• KRKA
• Bimeda
• CP-Pharma
• aniMedica

Top Two Companies

• Zoetis

Company-specific Germany revenue share is not supplied and should not be represented by an unsupported percentage. Its competitive positioning is strengthened by Rimadyl, Librela and the 2026 EU launch of Lenivia. Lenivia delivers up to three months of OA pain control from one injection, while Librela is monthly. Zoetis reported nearly 25 million Librela doses distributed globally by December 2024, providing evidence of substantial international adoption of biologic pain management.

• Boehringer Ingelheim

A defensible Germany-specific percentage share is likewise unavailable from the supplied dataset. The company maintains established NSAID positioning through products including Metacam and Previcox, covering meloxicam and firocoxib formulations for pain and inflammation. Its portfolio emphasizes multimodal treatment involving medication, weight management, exercise, physical therapy and adjunct approaches, positioning the company across conventional veterinary anti-inflammatory pathways.

Recent Developments in Germany Veterinary Analgesics Anti-Inflammatory Market

• 2026: Zoetis launched Lenivia in the European Union, introducing a three-month anti-NGF monoclonal-antibody option for canine osteoarthritis pain.
• 2025: The European Commission granted marketing authorization to Lenivia for reducing osteoarthritis-associated pain in dogs.
• 2025: EMA's CVMP issued a positive opinion recommending authorization of Lenivia, supporting expansion of longer-acting veterinary biologics.
• 2025: Zoetis published results from a 56-day study directly comparing Librela with meloxicam; 44 Librela-treated and 33 meloxicam-treated dogs completed the study.
• 2025: Zoetis updated the U.S. Librela label based on post-approval experience; the company reported nearly 25 million doses distributed globally as of December 2024, providing additional pharmacovigilance evidence relevant to the international veterinary pain-management landscape.

Research Methodology

The assessment uses the supplied 2025, 2026 and 2034 quantitative tables as the mandatory primary basis for revenue, segment contribution and CAGR calculations. Percentage shares were calculated by dividing individual 2026 segment values by their corresponding supplied totals: NSAIDs represent approximately 48.4%, opioids 31.6%, adjunctive analgesics 20.0%, companion animals 56.9%, and livestock animals 43.1%. External sources were used only for contextual production, animal-population, technology and recent-development evidence. No unsupported county-level, route-level, indication-level, channel-level, end-user-level or company-share estimates were introduced.